Details of the Drug Formulations

General Information of Drug (ID: DMBFZ6L)

Drug Name
Remdesivir Drug Info
Synonyms L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Approved [1]
Ebola virus infection 1D60.0 Phase 1 [2]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [3]
Cross-matching ID
PubChem CID
121304016
ChEBI ID
CHEBI:145994
CAS Number
1809249-37-3
TTD ID
D01ICI
ACDINA ID
D01380

Full List of Drug Formulations Containing This Drug

Remdesivir 100mg/20ml solution
Company Formulation ID FDA Description
Gilead Sciences F23877 Betadex Sulfobutyl Ether Sodium; Water For Injection; Hydrochloric Acid; Sodium Hydroxide
------------------------------------------------------------------------------------
Remdesivir 100mg/vial powder
Company Formulation ID FDA Description
Gilead Sciences F23876 Betadex Sulfobutyl Ether Sodium; Hydrochloric Acid; Sodium Hydroxide
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.